Clinical Presentations and Outcomes of Bile Duct Loss Caused by Drugs and Herbal and Dietary Supplements

Overview

Journal Hepatology

Specialty Gastroenterology

Date 2016 Dec 17

PMID 27981596

Citations 43

Authors

Herbert L Bonkovsky

David E Kleiner

Jiezhun Gu

Joseph A Odin

Mark W Russo

Victor M Navarro

Robert J Fontana

Marwan S Ghabril

Huiman Barnhart

Jay H Hoofnagle

Affiliations

Soon will be listed here.

Abstract

Conclusion: Bile duct loss during acute cholestatic hepatitis is an ominous early indicator of possible VBDS, for which at present there are no known means of prevention or therapy. (Hepatology 2017;65:1267-1277).

Citing Articles

Drug-Induced Liver Injury in Patients With Chronic Liver Disease.

Ghabril M, Vuppalanchi R, Chalasani N Liver Int. 2025; 45(3):e70019.

PMID: 39927421 PMC: 11808633. DOI: 10.1111/liv.70019.

Role of liver biopsy in the management of idiosyncratic DILI.

Kleiner D Liver Int. 2024; 45(3):e16097.

PMID: 39254214 PMC: 11815619. DOI: 10.1111/liv.16097.

Estimated Exposure to 6 Potentially Hepatotoxic Botanicals in US Adults.

Likhitsup A, Chen V, Fontana R JAMA Netw Open. 2024; 7(8):e2425822.

PMID: 39102266 PMC: 11301549. DOI: 10.1001/jamanetworkopen.2024.25822.

Glucocorticoid efficacy and treatment strategies for drug-induced liver injury: a literature review.

Wang P, Guo G, Jiang S, Ding D, Yang J, Lu Y Mol Biol Rep. 2024; 51(1):879.

PMID: 39083110 DOI: 10.1007/s11033-024-09806-w.

Clinical characteristics and HLA associations of azithromycin-induced liver injury.

Conlon C, Li Y, Ahmad J, Barnhart H, Fontana R, Ghabril M Aliment Pharmacol Ther. 2024; 60(6):787-795.

PMID: 38988034 PMC: 11587661. DOI: 10.1111/apt.18160.

References

Sarganas G, Orzechowski H, Klimpel A, Thomae M, Kauffmann W, Herbst H . Severe sustained cholestatic hepatitis following temozolomide in a patient with glioblastoma multiforme: case study and review of data from the FDA adverse event reporting system. Neuro Oncol. 2012; 14(5):541-6. PMC: 3337307. DOI: 10.1093/neuonc/nos056. View

Davies M, Harrison R, Elias E, Hubscher S . Antibiotic-associated acute vanishing bile duct syndrome: a pattern associated with severe, prolonged, intrahepatic cholestasis. J Hepatol. 1994; 20(1):112-6. DOI: 10.1016/s0168-8278(05)80476-3. View

Kleiner D, Chalasani N, Lee W, Fontana R, Bonkovsky H, Watkins P . Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology. 2013; 59(2):661-70. PMC: 3946736. DOI: 10.1002/hep.26709. View

Smith L, Ignacio J, Winesett M, Kaiser G, Lacson A, Gilbert-Barness E . Vanishing bile duct syndrome: amoxicillin-clavulanic acid associated intra-hepatic cholestasis responsive to ursodeoxycholic acid. J Pediatr Gastroenterol Nutr. 2005; 41(4):469-73. DOI: 10.1097/01.mpg.0000178086.44155.73. View

Richardet J, Mallat A, Zafrani E, Blazquez M, Bognel J, Campillo B . Prolonged cholestasis with ductopenia after administration of amoxicillin/clavulanic acid. Dig Dis Sci. 1999; 44(10):1997-2000. DOI: 10.1023/a:1026610015899. View

Reau N, Jensen D . Vanishing bile duct syndrome. Clin Liver Dis. 2008; 12(1):203-17, x. DOI: 10.1016/j.cld.2007.11.007. View

Forbes G, Jeffrey G, Shilkin K, REED W . Carbamazepine hepatotoxicity: another cause of the vanishing bile duct syndrome. Gastroenterology. 1992; 102(4 Pt 1):1385-8. View

Rockey D, Seeff L, Rochon J, Freston J, Chalasani N, Bonacini M . Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology. 2010; 51(6):2117-26. PMC: 3249230. DOI: 10.1002/hep.23577. View

Juricic D, Danica J, Hrstic I, Irena H, Radic D, Davor R . Vanishing bile duct syndrome associated with azithromycin in a 62-year-old man. Basic Clin Pharmacol Toxicol. 2009; 106(1):62-5. DOI: 10.1111/j.1742-7843.2009.00474.x. View

10.

Orman E, Conjeevaram H, Vuppalanchi R, Freston J, Rochon J, Kleiner D . Clinical and histopathologic features of fluoroquinolone-induced liver injury. Clin Gastroenterol Hepatol. 2011; 9(6):517-523.e3. PMC: 3718017. DOI: 10.1016/j.cgh.2011.02.019. View

11.

deLemos A, Ghabril M, Rockey D, Gu J, Barnhart H, Fontana R . Amoxicillin-Clavulanate-Induced Liver Injury. Dig Dis Sci. 2016; 61(8):2406-2416. PMC: 4945382. DOI: 10.1007/s10620-016-4121-6. View

12.

Desmet V . Histopathology of chronic cholestasis and adult ductopenic syndrome. Clin Liver Dis. 2004; 2(2):249-64, viii. DOI: 10.1016/s1089-3261(05)70006-4. View

13.

Robinson W, Habr F, Manlolo J, Bhattacharya B . Moxifloxacin associated vanishing bile duct syndrome. J Clin Gastroenterol. 2009; 44(1):72-3. DOI: 10.1097/MCG.0b013e3181a51af9. View

14.

Hayashi P, Rockey D, Fontana R, Tillmann H, Kaplowitz N, Barnhart H . Death and liver transplantation within 2 years of onset of drug-induced liver injury. Hepatology. 2017; 66(4):1275-1285. PMC: 5605419. DOI: 10.1002/hep.29283. View

15.

Chalasani N, Bonkovsky H, Fontana R, Lee W, Stolz A, Talwalkar J . Features and Outcomes of 899 Patients With Drug-Induced Liver Injury: The DILIN Prospective Study. Gastroenterology. 2015; 148(7):1340-52.e7. PMC: 4446235. DOI: 10.1053/j.gastro.2015.03.006. View

16.

Degott C, Feldmann G, Larrey D, Grange D, Machayekhi J, Moreau A . Drug-induced prolonged cholestasis in adults: a histological semiquantitative study demonstrating progressive ductopenia. Hepatology. 1992; 15(2):244-51. DOI: 10.1002/hep.1840150212. View

17.

Bhayana H, Appasani S, Thapa B, Das A, Singh K . Lamotrigine-induced vanishing bile duct syndrome in a child. J Pediatr Gastroenterol Nutr. 2011; 55(6):e147-8. DOI: 10.1097/MPG.0b013e31823c2500. View

18.

Mason M, Adeyi O, Fung S, Millar B . Vanishing bile duct syndrome in the context of concurrent temozolomide for glioblastoma. BMJ Case Rep. 2014; 2014. PMC: 4248108. DOI: 10.1136/bcr-2014-208117. View

19.

Moy B, Dojki F, Scholes J, Hoffman M . Azithromycin-Induced Cholestatic Hepatitis. Conn Med. 2015; 79(4):213-5. View

20.

Fontana R, Watkins P, Bonkovsky H, Chalasani N, Davern T, Serrano J . Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf. 2009; 32(1):55-68. PMC: 3637941. DOI: 10.2165/00002018-200932010-00005. View